Kura Oncology (KURA) Return on Capital Employed (2011 - 2026)
Kura Oncology's (KURA) quarterly Return on Capital Employed came in at 46.14% in Q1 2026, down 4404.0% year-on-year from 1.07% in Q1 2025, and down 2.4% on a QoQ basis from 45.06% in Q4 2025.
Kura Oncology (KURA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Kura Oncology (KURA) has 7 years of Return on Capital Employed data on file, last reported at 46.14% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 4404.0% year-over-year to 46.14% in Q1 2026; TTM through Mar 2026 was 46.14%, a 4404.0% decrease from a year earlier, with the FY2025 full-year figure at 48.02%, down 1128.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 46.14%, down from 45.06% in the prior quarter.
- Over the last five years, Return on Capital Employed for KURA reached as high as 0.32% in Q4 2024 and fell as low as 46.14% in Q1 2026.
- Historically, Return on Capital Employed has averaged 18.01% across 3 years, with a median of 10.45% in 2024.
- On a YoY basis, Return on Capital Employed climbed as much as 2913 bps in 2025 and fell as far as 4538 bps in 2025.
- Year by year, Return on Capital Employed stood at 0.32% in 2024, then sank by 14177 bps to 45.06% in 2025, then retreated by 2 bps to 46.14% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 46.14% in Q1 2026, 45.06% in Q4 2025, and 4.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Kura Oncology | 925.97 Mn | 925.97 Mn | 18.00 Mn | -46.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.14% |
| Dec 31, 2025 | -45.06% |
| Sep 30, 2025 | -4.46% |
| Jun 30, 2025 | -0.77% |
| Mar 31, 2025 | -2.11% |
| Dec 31, 2024 | 0.32% |
| Sep 30, 2024 | -33.59% |
| Jun 30, 2024 | -19.83% |
| Mar 31, 2024 | -10.45% |
| Dec 31, 2014 | 1.03% |
| Mar 31, 2013 | 23.00% |
| Dec 31, 2012 | 23.83% |
| Sep 30, 2012 | 26.26% |
| Jun 30, 2012 | 29.96% |
| Mar 31, 2012 | 28.47% |
| Dec 31, 2011 | 35.45% |
| Sep 30, 2011 | 40.02% |
| Jun 30, 2011 | 37.64% |